Drug Type Antibody drug conjugate (ADC) |
Synonyms BCG 019, BCG019 |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | CN | 08 Apr 2024 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 08 Apr 2024 | |
Stomach Cancer | Preclinical | CN | 08 Apr 2024 |